Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Diabetes and lipids].

Monika Lechleitner1, Heinz Drexel

  • 1Universitätsklinik für Innere Medizin, Anichstrasse 35, 6020 Innsbruck, Osterreich. monika.lechleitner@uibk.ac.at

Wiener Medizinische Wochenschrift (1946)
|December 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating Human Epididymis Protein 4 Predicts 10-Year Mortality and Major Adverse Cardiovascular Events in Patients With Peripheral Artery Disease.

European journal of clinical investigation·2026
Same author

[Antihyperglycemic treatment of type 2 diabetes mellitus (Update 2026)].

Wiener klinische Wochenschrift·2026
Same author

[Diagnostics and treatment of type 1 diabetes mellitus (Update 2026)].

Wiener klinische Wochenschrift·2026
Same author

[Individualizing antihypertensive therapy in diabetes mellitus. Guidelines of the Austrian Diabetes Association (Update 2026)].

Wiener klinische Wochenschrift·2026
Same author

[Lipids - Diagnostics and treatment in diabetes mellitus (Update 2026)].

Wiener klinische Wochenschrift·2026
Same author

[Cardiovascular diseases and heart failure in diabetes: diagnostics and management (Update 2026)].

Wiener klinische Wochenschrift·2026
Same journal

Regenerative therapies in rehabilitation with interfaces with occupational medicine, geriatrics, and oncology: the example of extracorporeal shock wave therapy.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Cerebral toxoplasmosis in patients with peripheral B-cell lymphoma : A case series and a literature review.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Post-pandemic rebound of rotavirus and adenovirus in pediatric gastroenteritis: a 6-year antigen-based surveillance study from Turkey.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Neuroaxis involvement in Chikungunya virus infection: a retrospective case series.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

A complicated case of a spinal Scedosporium apiospermum infection with a favorable outcome-case report.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Wiener medizinische Wochenschrift (1946)·2026
See all related articles

Diabetic dyslipidemia increases cardiovascular risk. Improving glycemic control and using statins or fibrates significantly reduces this risk in patients with type 1 and type 2 diabetes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Context:

  • Dyslipidemia is a primary cardiovascular risk factor, particularly in type 2 diabetes mellitus.
  • Insulin resistance, a hallmark of metabolic syndrome, correlates with an atherogenic lipoprotein profile.
  • Poor glycemic control in type 1 diabetes elevates plasma triglyceride levels.

Purpose:

  • To outline the management strategies for diabetic dyslipidemia.
  • To emphasize the importance of glycemic control and lifestyle modifications.
  • To highlight the necessity of lipid-lowering drug therapy for achieving target LDL-cholesterol levels.

Summary:

  • Treatment involves improving glycemic control in both type 1 and type 2 diabetes.
  • Lifestyle changes, including diet and exercise, are crucial components of management.

Related Experiment Videos

  • Lipid-lowering therapy, particularly statins and fibrates, is essential for reducing cardiovascular risk, as evidenced by major trials.

    • Impact:

    • Diabetic patients face cardiovascular risks equivalent to those with established cardiovascular disease.
    • Achieving strict LDL-cholesterol targets (below 100 mg/dL) is vital.
    • Evidence from large trials confirms that statin and fibrate therapies significantly mitigate cardiovascular risk in diabetic populations.